Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

Glioblastoma (GBM) is a highly malignant brain tumor with poor survival and prognosis. Randomized trials have demonstrated that chemotherapy improves survival in patients with GBM. This study aims to examine the clinical characteristics that are potentially associated with the efficacy of chemothera...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2021-01, Vol.21 (1), p.81-81, Article 81
Main Authors: Wen, Jieqiong, Chen, Wanbin, Zhu, Yayun, Zhang, Pengbo
Format: Article
Language:English
Subjects:
Age
Brain cancer
Brain tumors
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical trials
Demographics
Diagnosis
Epidemiology
Glioblastoma
Glioblastoma multiforme
Medical prognosis
Patient outcomes
Patients
Prognosis
Radiation therapy
Risk factors
SEER
Statistical analysis
Surgery
Surveillance
Survival
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma (GBM) is a highly malignant brain tumor with poor survival and prognosis. Randomized trials have demonstrated that chemotherapy improves survival in patients with GBM. This study aims to examine the clinical characteristics that are potentially associated with the efficacy of chemotherapy and the risk factors of GBM. A total of 25,698 patients diagnosed with GBM were identified between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER). The clinical and demographic variables between groups were examined by Student's t-test and Pearson's chi-square test. GBM-specific survival (GBMSS) and overall survival (OS) were evaluated using the Kaplan-Meier method with the log-rank test. Univariable and multivariable analyses were also performed using the Cox proportional hazards model to identify statistically significant prognostic factors. Patients who received chemotherapy had better overall survival (median OS 13 vs. Three months, HR = 1.9224, 95%CI 1.8571-1.9900, p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-021-07800-0